CD8A and gastric cancer: SCFAs bind specifically to Hydroxycarboxylic acid receptor 2(HCAR2, also called GPR109A), which selectively recognizes butyrate, inhibiting gastric cancer progression by enhancing CD8+ T-cell–mediated cytotoxicity, including that of CAR-Claudin 18.2+ CD8+ T cells (59).